ClinicalTrials.govpublic full text
A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma
head and neck squamous cell carcinoma, recurrent/metastatic head and neck squamous cell carcinoma, cdkn2a gene variant, cdk4/6 inhibitor, antibody-drug conjugate, egfr inhibitor, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 813932
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.